课题基金 / 基金详情

Discovery of ML324, a JMJD2 Demethylase Epigenetic Modulator as Potential Antiviral

Discovery of ML324, a JMJD2 Demethylase Epigenetic Modulator as Potential Antiviral
ML324 的发现,一种 JMJD2 去甲基酶表观遗传调节剂作为潜在的抗病毒药物
批准号:
9205748
负责人:
David Maloney
金额:
$11.4万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至

项目摘要

项目成果

David Maloney的其他基金

相关文献

中文摘要
翻译
项目亮点:探针分子的特点是在体内和体外ADME性能。几种顶级活性物质进行了选择性分析,并交付给合作者,以在各种肿瘤学模型中进行表征。 在此期间,NCGC促进并保持了与NIH和校外研究人员的180多项积极合作,促进了整个人类疾病谱的药物发现工作。 这些努力已经导致了100多个高通量筛选和近60个药物化学活动,为我们的合作者和一般研究社区提供了丰富的出版物和有前途的小分子线索。 此外,NCGC还承担了一系列信息挑战,以更好地利用现有的药物和疾病靶点信息,并为公众提供易于获取的资源,进一步促进人类疾病新疗法的开发。
英文摘要
Project highlights: the probe molecule was characterized for in vivo and in vitro ADME properties. Several top actives were profiled for selectivity and delivered to collaborators to characterize in various oncology models. During this period, the NCGC has fostered and maintained over 180 active collaborations with both NIH and extramural investigators, facilitating drug discovery efforts across the entire spectrum of human disease. These efforts have led to over 100 high-throughput screens and nearly 60 medicinal chemistry campaigns, providing our collaborators and the general research community a wealth of publications and promising small molecule leads. In addition, the NCGC has undertaken a number of informatic challenges to make better use of existing drug and disease target information and provide the general public with easily accessible resources, further catalyzing the development of new therapies for human disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
ML199: Inhibitor of Ape1 as a Lead for Cancer Therapeutics
Inhibitors of p53-S100B interaction for melanoma
Implications of 12-Lipoxygenase and NOX-1 in beta-Cell dysfunction, a potential target for Diabetes
Identification of Inhibitors of human Lactate Dehydrogenase A (LDHA) as Anti-cancer Agents